CR20110118A - Tratamiento de enfermedades autoinmunes e inflamatorias - Google Patents

Tratamiento de enfermedades autoinmunes e inflamatorias

Info

Publication number
CR20110118A
CR20110118A CR20110118A CR20110118A CR20110118A CR 20110118 A CR20110118 A CR 20110118A CR 20110118 A CR20110118 A CR 20110118A CR 20110118 A CR20110118 A CR 20110118A CR 20110118 A CR20110118 A CR 20110118A
Authority
CR
Costa Rica
Prior art keywords
treatment
autoimmune
inflammatory diseases
biological activity
multiple sclerosis
Prior art date
Application number
CR20110118A
Other languages
English (en)
Inventor
Stewart Leung
Lixin Li
Xuebin Liu
Hongtao Lu
Ping Tsui
Jingwu Zang
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of CR20110118A publication Critical patent/CR20110118A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Transplantation (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención proporciona nuevos procedimientos de tratamiento de la esclerosis múltiple y otras enfermedades autoinmunitarias o trastornos inflamatorios, y antagonistas, que incluyen proteínas de unión aisladas para su uso en los nuevos procedimientos. Se proporciona un procedimiento de tratamiento de la esclerosis múltiple que comprende la neutralización de la actividad biológica de la IL-7 mediante la unión a CD127 o a IL-7. Las proteínas de unión aisladas también pueden neutralizar la actividad biológica de la TSLP.
CR20110118A 2008-08-08 2011-03-03 Tratamiento de enfermedades autoinmunes e inflamatorias CR20110118A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US8729408P 2008-08-08 2008-08-08
US16980109P 2009-04-16 2009-04-16
US21862709P 2009-06-19 2009-06-19

Publications (1)

Publication Number Publication Date
CR20110118A true CR20110118A (es) 2011-07-28

Family

ID=41382165

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20110118A CR20110118A (es) 2008-08-08 2011-03-03 Tratamiento de enfermedades autoinmunes e inflamatorias

Country Status (23)

Country Link
US (2) US20100040616A1 (es)
EP (1) EP2318442A1 (es)
JP (1) JP2011530533A (es)
KR (1) KR20110044777A (es)
CN (1) CN102177179A (es)
AR (1) AR072985A1 (es)
AU (1) AU2009279471A1 (es)
BR (1) BRPI0916945A2 (es)
CA (1) CA2733432A1 (es)
CL (1) CL2011000269A1 (es)
CO (1) CO6341640A2 (es)
CR (1) CR20110118A (es)
DO (1) DOP2011000041A (es)
EA (1) EA201100150A1 (es)
IL (1) IL211034A0 (es)
MA (1) MA32621B1 (es)
MX (1) MX2011001477A (es)
NZ (1) NZ590994A (es)
PE (1) PE20110382A1 (es)
TW (1) TW201018482A (es)
UY (1) UY32038A (es)
WO (1) WO2010017468A1 (es)
ZA (1) ZA201100974B (es)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8171134B2 (en) * 2009-03-18 2012-05-01 At&T Intellectual Property I, L.P. Methods and apparatus to characterize and predict network health status
NZ601271A (en) 2010-01-28 2014-09-26 Glaxo Group Ltd Cd127 binding proteins
WO2011100567A1 (en) * 2010-02-11 2011-08-18 The Board Of Trustees Of The Leland Stanford Junior University Therapeutic inhibition of granulocyte function in demyelinating disease
AU2014201648B2 (en) * 2010-02-24 2016-05-12 Rinat Neuroscience Corp. Antagonist anti-il-7 receptor antibodies and methods
US8298535B2 (en) 2010-02-24 2012-10-30 Rinat Neuroscience Corp. Anti-IL-7 receptor antibodies
EP2578232A4 (en) * 2010-06-02 2013-11-20 Dainippon Sumitomo Pharma Co TREATMENT FOR AUTOIMMUN DISEASES AND ALLERGIC DISEASES
US20130295111A1 (en) * 2010-08-10 2013-11-07 The Scripps Research Institute Methods and compositions for treating disorders associated with hyperactive immune system
EP3252076B1 (en) 2011-01-14 2019-09-04 The Regents Of The University Of California Diagnostic use of antibodies against ror-1 protein
EP2583980A1 (en) 2011-10-19 2013-04-24 Effimune Antibodies directed against the alpha chain of IL7 receptor - their use for the preparation of drug candidates
FR2988479B1 (fr) * 2012-03-23 2014-12-19 Hospices Civils Lyon Procede de determination de la susceptibilite aux infections nosocomiales
EP2955196A1 (en) * 2014-06-10 2015-12-16 Effimune Antibodies directed against CD127
WO2016044189A1 (en) * 2014-09-15 2016-03-24 Genentech, Inc. Methods of treating cancer using pd-1 axis binding antagonist and il-17 binding antagonists
WO2016059512A1 (en) 2014-10-18 2016-04-21 Pfizer Inc. Anti-il-7r antibody compositions
EP3268032A1 (en) * 2015-03-11 2018-01-17 GlaxoSmithKline Intellectual Property Development Limited Tslp binding proteins
WO2017055966A1 (en) 2015-10-01 2017-04-06 Pfizer Inc. Low viscosity antibody compositions
CA2997809A1 (en) 2015-10-07 2017-04-13 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Il-7r-alpha specific antibodies for treating acute lymphoblastic leukemia
CN109195987B (zh) 2016-02-29 2022-05-27 Ose免疫疗法 针对IL7受体胞外域的α链的非拮抗性抗体及其在癌症治疗中的应用
ES2867900T3 (es) * 2016-12-09 2021-10-21 Ose Immunotherapeutics Anticuerpos y polipéptidos dirigidos contra CD127
JOP20190243A1 (ar) 2017-04-12 2019-10-13 Medimmune Llc علاج الربو بجسم مضاد لـ tslp
BR112021014106A2 (pt) 2019-01-22 2021-10-13 Bristol-Myers Squibb Company Anticorpos contra subunidade alfa de il-7r e usos dos mesmos
CN111662381B (zh) * 2019-03-07 2022-06-07 瑞阳(苏州)生物科技有限公司 人IL-1β蛋白结合分子及其编码基因和应用
TW202140550A (zh) 2020-01-29 2021-11-01 瑞士商諾華公司 使用抗ｔｓｌｐ抗體治療炎性或阻塞性氣道疾病之方法
US20230073888A1 (en) 2020-02-13 2023-03-09 Amgen Inc. Treatment of atopic dermatitis with anti-tslp antibody
IL295042A (en) 2020-02-13 2022-09-01 Amgen Inc Human anti-tslp antibody formulations and methods for treating inflammatory disease
CA3167975A1 (en) 2020-02-18 2021-08-26 Amgen, Inc. Formulations of human anti-tslp antibodies and methods of using the same
CN116547002A (zh) 2020-12-02 2023-08-04 葛兰素史密斯克莱知识产权发展有限公司 Il-7结合蛋白及其在医学疗法中的用途
TW202413441A (zh) 2022-05-27 2024-04-01 英商葛蘭素史密斯克藍智慧財產發展有限公司 TNF-α結合蛋白及IL-7結合蛋白於醫藥治療之用途
WO2024163978A2 (en) 2023-02-02 2024-08-08 Medimmune, Llc Treatment of chronic rhinosinusitis with anti-tslp antibody

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5194375A (en) * 1989-06-15 1993-03-16 Immunex Corporation Dna encoding interleukin-7 receptors and methods of use
US5859205A (en) * 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
EP0667395A4 (en) * 1993-06-01 1996-07-03 Toray Industries MONOCLONAL ANTIBODIES, APPLICATION AND PRODUCTION METHOD.
US20050054054A1 (en) * 2002-11-12 2005-03-10 Foss Francine M. Interleukin-7 molecules with altered biological properties
US20090130123A1 (en) * 2004-06-15 2009-05-21 Erol Fikrig Antibodies to west nile virus polypeptides
WO2006052660A2 (en) * 2004-11-04 2006-05-18 Childrens Hospital Los Angeles Research Institute Il-7 receptor blockade to suppress immunity
PE20061391A1 (es) * 2005-02-14 2007-01-09 Wyeth Corp Anticuerpos para interleucina-17f y otros antagonistas de la senalizacion de il-17f
CA2513350A1 (en) * 2005-03-02 2006-09-02 Sydney West Area Health Service Treatment for multiple sclerosis
GB2434578A (en) * 2006-01-26 2007-08-01 Univ Basel Transgenic animals

Also Published As

Publication number Publication date
AU2009279471A1 (en) 2010-02-11
MA32621B1 (fr) 2011-09-01
NZ590994A (en) 2012-09-28
WO2010017468A1 (en) 2010-02-11
KR20110044777A (ko) 2011-04-29
CA2733432A1 (en) 2010-02-11
EP2318442A1 (en) 2011-05-11
MX2011001477A (es) 2011-03-25
AR072985A1 (es) 2010-10-06
PE20110382A1 (es) 2011-06-27
DOP2011000041A (es) 2011-02-28
US20100040616A1 (en) 2010-02-18
TW201018482A (en) 2010-05-16
UY32038A (es) 2010-03-26
CL2011000269A1 (es) 2012-07-20
ZA201100974B (en) 2012-10-31
CN102177179A (zh) 2011-09-07
CO6341640A2 (es) 2011-11-21
EA201100150A1 (ru) 2011-10-31
US20110287000A1 (en) 2011-11-24
IL211034A0 (en) 2011-04-28
JP2011530533A (ja) 2011-12-22
BRPI0916945A2 (pt) 2015-11-24

Similar Documents

Publication Publication Date Title
CR20110118A (es) Tratamiento de enfermedades autoinmunes e inflamatorias
ECSP12012211A (es) Composiciones de anticuerpos anti-factor de crecimiento nervioso (ngf)
CO6592067A2 (es) Proteinas de elance a cd 127
ECSP077280A (es) Moduladores de quinasa de pirrolo-piridina
CR20120248A (es) Inmunoglobulinas con dominio variable dual y usos de las mismas
EA201370081A1 (ru) Антитела к cd48 и их применение
BR112012009846B8 (pt) método in vitro e kit para detecção de um anticorpo antifármaco de isotipo ige, e uso de um anticorpo antifármaco de isotipo ige no tratamento de distúrbio mediado por ige
UY32808A (es) Inmunoglobulinas como dominio variable dual y usos de las mismas
CL2014003110A1 (es) Anticuerpo anti-fcrn; secuencias que lo codifican; vector; célula huésped; proceso de producción; composición farmacéutica que lo comprende; uso para el tratamiento de enfermedad autoinmune; y ensayo para probar la capacidad de un anticuerpo para bloquear la actividad de fcrn humano.
TW200745109A (en) Pyrrolo-pyridine kinase modulators
EA202090031A3 (ru) Человеческие антитела против gfr3 и способы их применения
EA200901621A1 (ru) Индукция толерогенного фенотипа у зрелых дендритных клеток
ECSP088751A (es) Anticuerpos contra la il-22 humana y usos para los mismos
UA107812C2 (en) Oktahidropirolo disubstituted [3,4-c] pyrrole receptors as orexin modulators
EA201390711A1 (ru) Гидроксиамидные соединения пиримидина в качестве ингибиторов деацетилаз белков и способы их применения
EA201390669A1 (ru) Способы и композиции для иммунотерапии заболеваний нервной системы
CO6531489A2 (es) Anticuerpo anti -tslp modificado por técnicas de ingenieria genética
BR112014000634A2 (pt) métodos para tratamento de incontinência associada com atividade sexual
CO6630193A2 (es) Inhibidores de la actividad de la proteína tirosina quinasa seleccionada
ECSP13012536A (es) Composiciones de anticuerpo y métodos de uso
UY33662A (es) Combinaciones que comprenden inhibidores de dhodh e inhibidores de cox
ATE489947T1 (de) Axomadol zur schmerzbehandlung bei arthrose
ES2586805T3 (es) Análogos de péptidos para tratar enfermedades y trastornos
ECSP056015A (es) Anticuerpos contra el receptor de il-21 humano y usos de los mismos
CR20110471A (es) Proteínas de unión específicas y sus usos

Legal Events

Date Code Title Description
FA Abandonment or withdrawal (granting procedure)